Finch Therapeutics

Finch Therapeutics Presents Data from Its Positive PRISM3 Trial of CP101 in Recurrent C. difficile Infection at Two Leading Medical Conferences

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Microbiology, Medical specialties, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, Branches of biology, CP101, Finch Therapeutics

The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.

Key Points: 
  • The data presented expand on the positive topline results previously reported from PRISM3, a randomized, placebo-controlled, multi-center, Phase 2 trial, which demonstrated that CP101 met the primary efficacy endpoint with a statistically significant improvement in the prevention of recurrent CDI compared to placebo.
  • CP101 is an investigational, orally administered microbiome drug that Finch is developing for conditions linked to microbiome dysfunction.
  • CP101 is in late-stage clinical development for the prevention of recurrent C. difficile infection.
  • Finchs Human-First Discovery platform enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.

Finch Therapeutics to Present Data from its Positive PRISM3 Trial of CP101, an Investigational Oral Microbiome Drug, at Two Leading Medical Conferences

Retrieved on: 
Friday, October 9, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Bacteria, Microbiology, Microbiomes, Inflammatory bowel disease, Clostridioides difficile infection, Clostridioides difficile, Infection, Dysbiosis, CP101, Finch Therapeutics

The PRISM3 results will be featured in an oral presentation on October 12 at 3:36 PM CEST.

Key Points: 
  • The PRISM3 results will be featured in an oral presentation on October 12 at 3:36 PM CEST.
  • The abstract (#LB21) is titled An Investigational Oral Microbiome Drug, CP101, for the Prevention of Recurrent C. difficile Infection: A Randomized, Placebo-Controlled, Multi-Center Trial (PRISM3).
  • CP101 is an investigational, oral microbiome drug that Finch is developing for conditions linked to microbiome dysfunction.
  • The company has a strategic partnership with Takeda Pharmaceuticals focused on the development of microbiome drugs for inflammatory bowel diseases.

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

Retrieved on: 
Friday, June 19, 2020
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Infectious diseases, Medical specialties, Medicine, Antibiotic-resistant bacteria, Clostridiaceae, Clostridioides difficile, Gram-positive bacteria, CP101, C. difficile Infections, Finch Therapeutics

Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome drug development company, announced today positive topline results from PRISM3, its multi-center, randomized, double-blind, placebo-controlled Phase 2 trial of CP101, an investigational oral microbiome drug, for the prevention of recurrent C. difficile infection (CDI).

Key Points: 
  • Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome drug development company, announced today positive topline results from PRISM3, its multi-center, randomized, double-blind, placebo-controlled Phase 2 trial of CP101, an investigational oral microbiome drug, for the prevention of recurrent C. difficile infection (CDI).
  • PRISM3 randomized 206 patients with recurrent CDI at 51 sites across the U.S. and Canada, representing the largest placebo-controlled trial to date of an oral microbiome drug.
  • CP101 is the first oral microbiome drug to meet its primary endpoint in a pivotal trial.
  • PRISM3 is expected to provide pivotal data to support the approval of CP101 for the prevention of recurrent CDI.

Finch Therapeutics Announces Appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors

Retrieved on: 
Wednesday, September 25, 2019
Mental health, Health, Infectious diseases, Pharmaceutical, Biotechnology, Finch Therapeutics, recurrent Clostridium difficile infection (CDI), Autism Spectrum Disorder (ASD)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors.

Key Points: 
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the appointment of Dr. Jo Viney and Domenic Ferrante to its Board of Directors.
  • We are delighted to have Jo and Dom join our Board of Directors, said Mark Smith, PhD, CEO of Finch.
  • Jo is on the advisory Board for HotSpot Therapeutics and is a member of the Board of Directors for Quench Bio and Carogen Corp in addition to Finch Therapeutics.
  • Finch Therapeutics Group, Inc. (Finch) is developing novel microbial therapies to serve patients with serious unmet medical needs.

Finch Therapeutics Raises $53 Million to Advance Microbiome-Based Therapies for Recurrent C. Difficile, Autism and other Disease Areas

Retrieved on: 
Thursday, August 22, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Psychiatry, Autism, Abnormal psychology, Psychiatric diagnosis, Medicine, Autism therapies, David Berry, Finch Therapeutics, Recurrent Clostridium difficile Infection (CDI), Autism Spectrum Disorder (ASD)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing.

Key Points: 
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing.
  • Compelling results from the PRISM3 trial may be sufficient to support FDA approval, based on recent communications with the agency.
  • The Series C proceeds will also enable Finch to accelerate the development of its FSM therapy for Autism Spectrum Disorder (ASD).
  • Finch Therapeutics Group, Inc. (Finch) is developing novel microbial therapies to serve patients with serious unmet medical needs.